GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Trinity Biotech PLC (NAS:TRIB) » Definitions » Cyclically Adjusted PB Ratio

Trinity Biotech (Trinity Biotech) Cyclically Adjusted PB Ratio : 0.08 (As of May. 14, 2024)


View and export this data going back to 1995. Start your Free Trial

What is Trinity Biotech Cyclically Adjusted PB Ratio?

As of today (2024-05-14), Trinity Biotech's current share price is $1.52. Trinity Biotech's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $20.09. Trinity Biotech's Cyclically Adjusted PB Ratio for today is 0.08.

The historical rank and industry rank for Trinity Biotech's Cyclically Adjusted PB Ratio or its related term are showing as below:

TRIB' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.08   Med: 0.67   Max: 2.27
Current: 0.08

During the past years, Trinity Biotech's highest Cyclically Adjusted PB Ratio was 2.27. The lowest was 0.08. And the median was 0.67.

TRIB's Cyclically Adjusted PB Ratio is ranked better than
91.67% of 132 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.985 vs TRIB: 0.08

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Trinity Biotech's adjusted book value per share data for the three months ended in Dec. 2023 was $-2.530. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $20.09 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Trinity Biotech Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Trinity Biotech's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Trinity Biotech Cyclically Adjusted PB Ratio Chart

Trinity Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.16 0.67 0.27 0.21 0.11

Trinity Biotech Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.21 0.20 0.21 0.17 0.11

Competitive Comparison of Trinity Biotech's Cyclically Adjusted PB Ratio

For the Diagnostics & Research subindustry, Trinity Biotech's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Trinity Biotech's Cyclically Adjusted PB Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Trinity Biotech's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Trinity Biotech's Cyclically Adjusted PB Ratio falls into.



Trinity Biotech Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Trinity Biotech's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=1.52/20.09
=0.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Trinity Biotech's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Trinity Biotech's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-2.53/120.1096*120.1096
=-2.530

Current CPI (Dec. 2023) = 120.1096.

Trinity Biotech Quarterly Data

Book Value per Share CPI Adj_Book
201403 40.958 100.573 48.914
201406 42.495 100.773 50.649
201409 41.307 100.474 49.380
201412 41.772 99.576 50.386
201503 42.677 99.975 51.272
201506 43.487 100.573 51.934
201509 44.031 100.274 52.741
201512 44.635 99.676 53.785
201603 44.339 99.676 53.428
201606 43.961 101.072 52.242
201609 45.532 100.274 54.539
201612 23.529 99.676 28.352
201703 23.648 100.374 28.298
201706 23.127 100.673 27.592
201709 25.417 100.474 30.384
201712 15.576 100.075 18.694
201803 15.715 100.573 18.768
201806 15.934 101.072 18.935
201809 16.287 101.371 19.298
201812 10.538 100.773 12.560
201903 10.566 101.670 12.482
201906 9.347 102.168 10.988
201909 9.313 102.268 10.938
201912 1.127 102.068 1.326
202003 0.184 102.367 0.216
202006 -0.170 101.769 -0.201
202009 1.691 101.072 2.010
202012 -0.531 101.072 -0.631
202103 -0.030 102.367 -0.035
202106 -0.119 103.364 -0.138
202109 0.194 104.859 0.222
202112 -0.076 106.653 -0.086
202203 -1.167 109.245 -1.283
202206 2.076 112.734 2.212
202209 0.870 113.431 0.921
202212 -0.286 115.425 -0.298
202303 -0.866 117.618 -0.884
202306 -1.489 119.611 -1.495
202309 -2.288 120.708 -2.277
202312 -2.530 120.110 -2.530

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Trinity Biotech  (NAS:TRIB) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Trinity Biotech Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Trinity Biotech's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Trinity Biotech (Trinity Biotech) Business Description

Traded in Other Exchanges
Address
IDA Business Park, Bray, County Wicklow, Dublin, IRL, A98 H5C8
Trinity Biotech PLC is in the business of development, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point of care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Premier, Immublot, EZ, Capita, and others. Geographically, it has two segments namely the Americas, and Rest of World - Ireland of which it derives a majority of its revenues from the Americas segment.